Report Thumbnail
Product Code LP091091146BSZ
Published Date 2023/3/2
English109 PagesGlobal

Global Telmisartan Market Growth 2023-2029Telecom_Media_ICT_Digital Market


Report Thumbnail
Product Code LP091091146BSZ◆The Mar 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/3/2
English 109 PagesGlobal

Global Telmisartan Market Growth 2023-2029Telecom_Media_ICT_Digital Market



Abstract


Summary

LPI (LP Information)' newest research report, the “Telmisartan Industry Forecast” looks at past sales and reviews total world Telmisartan sales in 2022, providing a comprehensive analysis by region and market sector of projected Telmisartan sales for 2023 through 2029. With Telmisartan sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Telmisartan industry. This Insight Report provides a comprehensive analysis of the global Telmisartan landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Telmisartan portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Telmisartan market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Telmisartan and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Telmisartan. The global Telmisartan market size is projected to grow from US$ 3178.1 million in 2022 to US$ 4050.8 million in 2029; it is expected to grow at a CAGR of 4050.8 from 2023 to 2029. United States market for Telmisartan is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. China market for Telmisartan is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Europe market for Telmisartan is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Global key Telmisartan players cover Pfizer, Teva, Boehringer Ingelheim, Novartis, Mylan, Reddy's Laboratories (UK), Hema Pharmaceuticals Pvt, Bayer and GSK, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022. This report presents a comprehensive overview, market shares, and growth opportunities of Telmisartan market by product type, application, key manufacturers and key regions and countries. Market Segmentation: Segmentation by type Injection Freeze-Dried Powder Segmentation by application Hospital Clinic Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Pfizer Teva Boehringer Ingelheim Novartis Mylan Reddy's Laboratories (UK) Hema Pharmaceuticals Pvt Bayer GSK Astellas Pharma Inc Nippon Boehringer Ingelheim Abbott Takeda Beijing Wansheng Pharmaceutical Key Questions Addressed in this Report What is the 10-year outlook for the global Telmisartan market? What factors are driving Telmisartan market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Telmisartan market opportunities vary by end market size? How does Telmisartan break out type, application? What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Telmisartan Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Telmisartan by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Telmisartan by Country/Region, 2018, 2022 & 2029
    • 2.2 Telmisartan Segment by Type
      • 2.2.1 Injection
      • 2.2.2 Freeze-Dried Powder
    • 2.3 Telmisartan Sales by Type
      • 2.3.1 Global Telmisartan Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Telmisartan Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Telmisartan Sale Price by Type (2018-2023)
    • 2.4 Telmisartan Segment by Application
      • 2.4.1 Hospital
      • 2.4.2 Clinic
      • 2.4.3 Others
    • 2.5 Telmisartan Sales by Application
      • 2.5.1 Global Telmisartan Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Telmisartan Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Telmisartan Sale Price by Application (2018-2023)
  • 3 Global Telmisartan by Company

    • 3.1 Global Telmisartan Breakdown Data by Company
      • 3.1.1 Global Telmisartan Annual Sales by Company (2018-2023)
      • 3.1.2 Global Telmisartan Sales Market Share by Company (2018-2023)
    • 3.2 Global Telmisartan Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Telmisartan Revenue by Company (2018-2023)
      • 3.2.2 Global Telmisartan Revenue Market Share by Company (2018-2023)
    • 3.3 Global Telmisartan Sale Price by Company
    • 3.4 Key Manufacturers Telmisartan Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Telmisartan Product Location Distribution
      • 3.4.2 Players Telmisartan Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Telmisartan by Geographic Region

    • 4.1 World Historic Telmisartan Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Telmisartan Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Telmisartan Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Telmisartan Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Telmisartan Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Telmisartan Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Telmisartan Sales Growth
    • 4.4 APAC Telmisartan Sales Growth
    • 4.5 Europe Telmisartan Sales Growth
    • 4.6 Middle East & Africa Telmisartan Sales Growth
  • 5 Americas

    • 5.1 Americas Telmisartan Sales by Country
      • 5.1.1 Americas Telmisartan Sales by Country (2018-2023)
      • 5.1.2 Americas Telmisartan Revenue by Country (2018-2023)
    • 5.2 Americas Telmisartan Sales by Type
    • 5.3 Americas Telmisartan Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Telmisartan Sales by Region
      • 6.1.1 APAC Telmisartan Sales by Region (2018-2023)
      • 6.1.2 APAC Telmisartan Revenue by Region (2018-2023)
    • 6.2 APAC Telmisartan Sales by Type
    • 6.3 APAC Telmisartan Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan
  • 7 Europe

    • 7.1 Europe Telmisartan by Country
      • 7.1.1 Europe Telmisartan Sales by Country (2018-2023)
      • 7.1.2 Europe Telmisartan Revenue by Country (2018-2023)
    • 7.2 Europe Telmisartan Sales by Type
    • 7.3 Europe Telmisartan Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Telmisartan by Country
      • 8.1.1 Middle East & Africa Telmisartan Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Telmisartan Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Telmisartan Sales by Type
    • 8.3 Middle East & Africa Telmisartan Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Telmisartan
    • 10.3 Manufacturing Process Analysis of Telmisartan
    • 10.4 Industry Chain Structure of Telmisartan
  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Telmisartan Distributors
    • 11.3 Telmisartan Customer
  • 12 World Forecast Review for Telmisartan by Geographic Region

    • 12.1 Global Telmisartan Market Size Forecast by Region
      • 12.1.1 Global Telmisartan Forecast by Region (2024-2029)
      • 12.1.2 Global Telmisartan Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Telmisartan Forecast by Type
    • 12.7 Global Telmisartan Forecast by Application
  • 13 Key Players Analysis

    • 13.1 Pfizer
      • 13.1.1 Pfizer Company Information
      • 13.1.2 Pfizer Telmisartan Product Portfolios and Specifications
      • 13.1.3 Pfizer Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 Pfizer Main Business Overview
      • 13.1.5 Pfizer Latest Developments
    • 13.2 Teva
      • 13.2.1 Teva Company Information
      • 13.2.2 Teva Telmisartan Product Portfolios and Specifications
      • 13.2.3 Teva Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Teva Main Business Overview
      • 13.2.5 Teva Latest Developments
    • 13.3 Boehringer Ingelheim
      • 13.3.1 Boehringer Ingelheim Company Information
      • 13.3.2 Boehringer Ingelheim Telmisartan Product Portfolios and Specifications
      • 13.3.3 Boehringer Ingelheim Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Boehringer Ingelheim Main Business Overview
      • 13.3.5 Boehringer Ingelheim Latest Developments
    • 13.4 Novartis
      • 13.4.1 Novartis Company Information
      • 13.4.2 Novartis Telmisartan Product Portfolios and Specifications
      • 13.4.3 Novartis Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Novartis Main Business Overview
      • 13.4.5 Novartis Latest Developments
    • 13.5 Mylan
      • 13.5.1 Mylan Company Information
      • 13.5.2 Mylan Telmisartan Product Portfolios and Specifications
      • 13.5.3 Mylan Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 Mylan Main Business Overview
      • 13.5.5 Mylan Latest Developments
    • 13.6 Reddy's Laboratories (UK)
      • 13.6.1 Reddy's Laboratories (UK) Company Information
      • 13.6.2 Reddy's Laboratories (UK) Telmisartan Product Portfolios and Specifications
      • 13.6.3 Reddy's Laboratories (UK) Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.6.4 Reddy's Laboratories (UK) Main Business Overview
      • 13.6.5 Reddy's Laboratories (UK) Latest Developments
    • 13.7 Hema Pharmaceuticals Pvt
      • 13.7.1 Hema Pharmaceuticals Pvt Company Information
      • 13.7.2 Hema Pharmaceuticals Pvt Telmisartan Product Portfolios and Specifications
      • 13.7.3 Hema Pharmaceuticals Pvt Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.7.4 Hema Pharmaceuticals Pvt Main Business Overview
      • 13.7.5 Hema Pharmaceuticals Pvt Latest Developments
    • 13.8 Bayer
      • 13.8.1 Bayer Company Information
      • 13.8.2 Bayer Telmisartan Product Portfolios and Specifications
      • 13.8.3 Bayer Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.8.4 Bayer Main Business Overview
      • 13.8.5 Bayer Latest Developments
    • 13.9 GSK
      • 13.9.1 GSK Company Information
      • 13.9.2 GSK Telmisartan Product Portfolios and Specifications
      • 13.9.3 GSK Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.9.4 GSK Main Business Overview
      • 13.9.5 GSK Latest Developments
    • 13.10 Astellas Pharma Inc
      • 13.10.1 Astellas Pharma Inc Company Information
      • 13.10.2 Astellas Pharma Inc Telmisartan Product Portfolios and Specifications
      • 13.10.3 Astellas Pharma Inc Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.10.4 Astellas Pharma Inc Main Business Overview
      • 13.10.5 Astellas Pharma Inc Latest Developments
    • 13.11 Nippon Boehringer Ingelheim
      • 13.11.1 Nippon Boehringer Ingelheim Company Information
      • 13.11.2 Nippon Boehringer Ingelheim Telmisartan Product Portfolios and Specifications
      • 13.11.3 Nippon Boehringer Ingelheim Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.11.4 Nippon Boehringer Ingelheim Main Business Overview
      • 13.11.5 Nippon Boehringer Ingelheim Latest Developments
    • 13.12 Abbott
      • 13.12.1 Abbott Company Information
      • 13.12.2 Abbott Telmisartan Product Portfolios and Specifications
      • 13.12.3 Abbott Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.12.4 Abbott Main Business Overview
      • 13.12.5 Abbott Latest Developments
    • 13.13 Takeda
      • 13.13.1 Takeda Company Information
      • 13.13.2 Takeda Telmisartan Product Portfolios and Specifications
      • 13.13.3 Takeda Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.13.4 Takeda Main Business Overview
      • 13.13.5 Takeda Latest Developments
    • 13.14 Beijing Wansheng Pharmaceutical
      • 13.14.1 Beijing Wansheng Pharmaceutical Company Information
      • 13.14.2 Beijing Wansheng Pharmaceutical Telmisartan Product Portfolios and Specifications
      • 13.14.3 Beijing Wansheng Pharmaceutical Telmisartan Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.14.4 Beijing Wansheng Pharmaceutical Main Business Overview
      • 13.14.5 Beijing Wansheng Pharmaceutical Latest Developments
  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.
Global Telmisartan Market Growth 2023-2029 | Telecom_Media_ICT_Digital Market Research Report - ShareFair Markets